NEWS
Morphocell Technologies Announces the Appointment of Dr. Anthony Cheung to its Board of Directors
![230829-StudioNouveau_0139Bcropped[91][70].jpg](https://static.wixstatic.com/media/137533_f9fcc31debff45d7924c03b5c80c1da9~mv2.jpg/v1/crop/x_159,y_0,w_1385,h_1337/fill/w_253,h_244,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/230829-StudioNouveau_0139Bcropped%5B91%5D%5B70%5D.jpg)
Laval, Québec – April 22, 2026 – Morphocell Technologies Inc., a biotechnology company pioneering next-generation tissue therapeutics for organ replacement, today announced the appointment of Dr. Anthony Cheung to its Board of Directors.
Dr. Cheung is the Founder and Chief Scientific Officer of enGene Therapeutics, Inc. (Nasdaq: ENGN), where he has played a central role in developing and translating a differentiated non-viral gene therapy platform for mucosal tissues. As co-inventor of enGene’s proprietary polymeric gene delivery technology, he has led its progression from early discovery through clinical-stage development, with a strong focus on product design and manufacturing scale-up.
A recognized leader in gene and cell therapies, Dr. Cheung brings deep expertise in translating complex biological platforms into clinically viable and industrially scalable medicines. During his tenure as CEO of enGene from 2012–2018, he built and expanded the company’s R&D and manufacturing capabilities, secured major venture and non-dilutive financing, and established strategic partnerships with leading pharmaceutical companies valued at over $2 billion. Under his leadership, enGene was recognized as BIOTECanada’s Biotech Company of the Year.
​
In his current role as Chief Scientific Officer, Dr. Cheung continues to oversee the advancement of enGene’s platform across multiple indications, including its lead program in bladder cancer. He holds a PhD in Physiology from Tulane University School of Medicine (New Orleans, USA) and has authored numerous peer-reviewed scientific publications, as well as being an inventor on multiple patents in gene delivery and polymer chemistry.
​
“Anthony brings exceptional expertise at the intersection of science, manufacturing, and clinical translation in advanced therapies,” said Dr. Massimiliano Paganelli, CEO and co-founder of Morphocell. “His experience in building and industrializing complex gene therapy platforms will be invaluable as we advance ReLiver® toward the clinic and continue to scale our engineered tissue platform.”
​​
“I am excited to join Morphocell at such a pivotal stage,” said Dr. Anthony Cheung. “The company’s novel approach to engineered tissues has the potential to redefine organ replacement therapy, and I look forward to supporting the translation of this paradigm-shifting innovation into scalable, clinically impactful treatments.”
​
Dr. Cheung’s appointment further strengthens Morphocell’s Board of Directors as the company enters its next phase of development and advances toward clinical studies.
​
About Morphocell Technologies:
Morphocell Technologies is a Montreal-based regenerative medicine company developing stem cell–derived tissue and organ replacement therapies. Its proprietary allogeneic platform is designed to address severe organ deficiencies, beginning with liver disease. The company’s lead product, ReLiver®, is an off-the-shelf engineered liver tissue intended to temporarily replace liver function and enable regeneration without the need for immunosuppression. Morphocell is committed to transforming the treatment paradigm for liver failure and other life-threatening conditions through innovation in regenerative medicine.
Media Contact:
Zaynah Ibrahim
Operations Manager
+1 (514) 373-6444 ext. 106